An in silico immunological approach for prediction of CD8+ T cell epitopes of Leishmania major proteins in susceptible BALB/c and resistant C57BL/6 murine models of infection

Infection, Genetics and Evolution

Volumn 9, Issue 3, 2009, Pages 344-350

  Guerfali, F Z ^a   Ben Abdallah, H ^a   Sghaier, R M ^a   Ben Aissa, K ^a   Mkannez, G ^a   Attia, H ^a   Laouini, D ^a  

^a WHO Collaborating Center for Research and Training in Leishmaniasis   (Tunisia)

Author keywords

BALB c; C57BL 6; CD8 T cells; Epitopes; In silico; Leishmania major; Prediction

Indexed keywords

ANTILEISHMANIAL AGENT; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTOZOAL PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE MODEL; DRUG DESIGN; FEMALE; INFECTION RESISTANCE; INFECTION SENSITIVITY; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SKIN LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; AUTOMATIC DATA PROCESSING; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; LEISHMANIA MAJOR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN SORTING SIGNALS; SEQUENCE ANALYSIS, PROTEIN;

LEISHMANIA MAJOR; MURINAE; MUS;

EID: 64749100632     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2008.02.011     Document Type: Article

References (44)

1. Alves C.R., Pontes de Carvalho L.C., Souza A.L., and De Simone S.G. A strategy for the identification of T-cell epitopes on Leishmania cysteine proteinases. Cytobios 104 (2001) 33-41
2. Antonelli L.R., Dutra W.O., Almeida R.P., Bacellar O., Carvalho E.M., and Gollob K.J. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol. Lett. 101 (2005) 226-230
3. Basta S., and Alatery A. The cross-priming pathway: a portrait of an intricate immune system. Scand. J. Immunol. 65 (2007) 311-319
4. Belkaid Y., Von Stebut E., Mendez S., Lira R., Caler E., Bertholet S., Udey M.C., and Sacks D. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168 (2002) 3992-4000
5. Bendtsen J.D., Nielsen H., von Heijne G., and Brunak S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340 (2004) 783-795
6. Bertholet S., Goldszmid R., Morrot A., Debrabant A., Afrin F., Collazo-Custodio C., Houde M., Desjardins M., Sher A., and Sacks D. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J. Immunol. 177 (2006) 3525-3533
7. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143 (1976) 1283-1288
8. Bottrel R.L., Dutra W.O., Martins F.A., Gontijo B., Carvalho E., Barral-Netto M., Barral A., Almeida R.P., Mayrink W., Locksley R., and Gollob K.J. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect. Immun. 69 (2001) 3232-3239
9. Brodskyn C.I., Barral A., Boaventura V., Carvalho E., and Barral-Netto M. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal leishmaniasis. J. Immunol. 159 (1997) 4467-4473
10. Da Conceicao-Silva F., Perlaza B., Louis J.A., and Romero P. Leishmania major infection in mice primes for specific major histocompatibility complex class I-restricted cytotoxic T cell responses. Eur. J. Immunol. 24 (1994) 2813-2817
11. da Silva R., and Sacks D.L. Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infect. Immun. 55 (1987) 2802-2806
12. De Luca P.M., Mayrink W., Alves C.R., Coutinho S.G., Oliveira M.P., Bertho A.L., Toledo V.P., Costa C.A., Genaro O., and Mendonca S.C. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 17 (1999) 1179-1185
13. den Haan J.M., and Bevan M.J. Antigen presentation to CD8+ T cells: cross-priming in infectious diseases. Curr. Opin. Immunol. 13 (2001) 437-441
14. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27 (2004) 305-318
15. Garg R., Gupta S.K., Tripathi P., Hajela K., Sundar S., Naik S., and Dube A. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 24 (2006) 2900-2909
16. Hanada K., Yewdell J.W., and Yang J.C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427 (2004) 252-256
17. Heath W.R., and Carbone F.R. Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. 11 (1999) 314-318
18. Hernandez A.G. Leishmanial excreted factors and their possible biological role. Ciba Found. Symp. 99 (1983) 138-156
19. Hill J.O., Auwas M., and North R.J. Elimination of CD4+ suppressor T cell from susceptible BALB/c mice release CD8+ T lymphocytes to mediate protective immunity against Leishmania. J. Exp. Med. 169 (1989) 1819-1827
20. Huber M., Timms E., Mak T.W., Rollinghoff M., and Lohoff M. Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect. Immun. 66 (1998) 3968
21. Kebaier C., Louzir H., Chenik M., Ben Salah A., and Dellagi K. Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response. Infect. Immun. 69 (2001) 4906-4915
22. Lemesre J.L., Holzmuller P., Cavaleyra M., Gonçalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 (2005) 2825-2840
23. Lemesre J.L., Holzmuller P., Gonçalves R.B., Bordoiseau G., Hugnet C., Cavaleyra M., and Papierok G. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 (2007) 4223-4234
24. Moore M.W., Carbone F.R., and Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54 (1988) 777-785
25. Murray H.W., Berman J.D., Davies C.R., and Saravia N.G. Advances in leishmaniasis. Lancet 366 (2005) 1561-1577
26. Overath P., and Harbecke D. Course of Leishmania infection in beta2-microglobulin-deficient mice. Immunol. Lett. 37 (1993) 13
27. Peters B., Bui H.H., Frankild S., Nielson M., Lundegaard C., Kostem E., Basch D., Lamberth K., Harndahl M., Fleri W., Wilson S.S., Sidney J., Lund O., Buus S., and Sette A. A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput. Biol. 2 (2006) e65
28. Pompeu M.M., Brodskyn C., Teixeira M.J., Clarencio J., Van Weyenberg J., Coelho I.C., Cardoso S.A., Barral A., and Barral-Netto M. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infect. Immun. 69 (2001) 7453-7460
29. Rammensee H., Bachmann J., Philipp N., Emmerich N., Bachor O.A., and Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1999) 213-219
30. Reche P.A., Glutting J.-P., and Reinherz E.L. Prediction of MHC class I binding peptides using profile motifs. Hum. Immunol. 63 (2002) 701-709
31. Rock K.L., York I.A., Saric T., and Goldberg A.L. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol. 80 (2002) 1-70
32. Rock K.L., York I.A., and Goldberg A.L. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 5 (2004) 670-677
33. Rosa R., Marques C., Rodrigues O.R., and Santos-Gomes G.M. Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response. Vaccine 6 (2007) 4525-4532
34. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2 (2002) 845-858
35. Stefani M.M., Muller I., and Louis J.A. Leishmania major-specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrophages. Eur. J. Immunol. 24 (1994) 746-752
36. Titus R.G., Milon G., Marchal G., Vassalli P., Cerottini J.C., and Louis J.A. Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis. Eur. J. Immunol. 17 (1987) 1429-1433
37. Tonui W.K., Mejia J.S., Hochberg L., Mbow M.L., Ryan J.R., Chan A.S., Martin S.K., and Titus R.G. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect. Immun. 72 (2004) 5654-5661
38. Tonui W.K., and Titus R.G. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/c mice. Am. J. Trop. Med. Hyg. 76 (2007) 579-584
39. Uzonna J.E., Wei G., Yurkowski D., and Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167 (2001) 6967-6974
40. Von Stebut E. Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur. J. Dermatol. 17 (2007) 115-122
41. Wang Z.E., Reiner S.L., Hatam F., Heinzel F.P., Bouvier J., Turck C.W., and Locksley R.M. Targeted activation of CD8+ T cells and infection of b-2 microglobulin deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J. Immunol. 151 (1993) 2077-2086
42. Yewdell J.W., Bennink J.R., and Hosaka Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 239 (1988) 637-640
43. Yewdell J.W. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell. Biol. 11 (2001) 294-297
44. BALB/c: a system for the prediction of peptide binding to H2d molecules, a haplotype of the BALB/c mouse. Nucleic Acids Res. 33 (2005) W180-W183